Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Reactive drug metabolites [[electronic resource] /] / Amit S. Kalgutkar ...[et. al.]
| Reactive drug metabolites [[electronic resource] /] / Amit S. Kalgutkar ...[et. al.] |
| Autore | Kalgutkar Amit S. <1965-> |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2012 |
| Descrizione fisica | 1 online resource (403 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) | KalgutkarAmit S. <1965-> |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Free radicals (Chemistry) - Physiological effect
Drugs - Metabolism |
| ISBN |
3-527-65574-3
1-283-60402-7 9786613916471 3-527-65576-X 3-527-65577-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Reactive Drug Metabolites; Contents; Preface; A Personal Foreword; 1 Origin and Historical Perspective on Reactive Metabolites; Abbreviations; 1.1 Mutagenesis and Carcinogenesis; 1.2 Detection of Reactive Metabolites; 1.3 Induction and Inhibition: Early Probes for Reactive Metabolites and Hepatotoxicants; 1.4 Covalent Binding and Oxidative Stress: Possible Mechanisms of Reactive Metabolite Cytotoxicity; 1.5 Activation and Deactivation: Intoxication and Detoxification; 1.6 Genetic Influences on Reactive Metabolite Formation
1.7 Halothane: the Role of Reactive Metabolites in Immune-Mediated Toxicity1.8 Formation of Reactive Metabolites, Amount Formed, and Removal of Liability; 1.9 Antibodies: Possible Clues but Inconclusive; 1.10 Parent Drug and Not Reactive Metabolites, Complications in Immune-Mediated Toxicity; 1.11 Reversible Pharmacology Should not be Ignored as a Primary Cause of Side Effects; 1.12 Conclusions: Key Points in the Introduction; References; 2 Role of Reactive Metabolites in Genotoxicity; Abbreviations; 2.1 Introduction; 2.2 Carcinogenicity of Aromatic and Heteroaromatic Amines 2.3 Carcinogenicity of Nitrosamines2.4 Carcinogenicity of Quinones and Related Compounds; 2.5 Carcinogenicity of Furan; 2.6 Carcinogenicity of Vinyl Halides; 2.7 Carcinogenicity of Ethyl Carbamate; 2.8 Carcinogenicity of Dihaloalkanes; 2.9 Assays to Detect Metabolism-Dependent Genotoxicity in Drug Discovery; 2.10 Case Studies in Eliminating Metabolism-Based Mutagenicity in Drug Discovery Programs; References; 3 Bioactivation and Inactivation of Cytochrome P450 and Other Drug-Metabolizing Enzymes; Abbreviations; 3.1 Introduction 3.2 Pharmacokinetic and Enzyme Kinetic Principles Underlying Mechanism-Based Inactivation and Drug-Drug Interactions3.2.1 Enzyme Kinetic Principles of Mechanism-Based Inactivation; 3.2.2 Pharmacokinetic Principles Underlying DDIs Caused by Mechanism-Based Inactivation; 3.3 Mechanisms of Inactivation of Cytochrome P450 Enzymes; 3.3.1 Quasi-Irreversible Inactivation; 3.3.2 Heme Adducts; 3.3.3 Protein Adducts; 3.4 Examples of Drugs and Other Compounds that are Mechanism-Based Inactivators of Cytochrome P450 Enzymes; 3.4.1 Amines; 3.4.2 Methylenedioxyphenyl Compounds 3.4.3 Quinones, Quinone Imines, and Quinone Methides3.4.4 Thiophenes; 3.4.5 Furans; 3.4.6 Alkynes; 3.4.7 2-Alkylimidazoles; 3.4.8 Other Noteworthy Cytochrome P450 Inactivators; 3.5 Mechanism-Based Inactivation of Other Drug-Metabolizing Enzymes; 3.5.1 Aldehyde Oxidase; 3.5.2 Monoamine Oxidases; 3.6 Concluding Remarks; References; 4 Role of Reactive Metabolites in Drug-Induced Toxicity - The Tale of Acetaminophen, Halothane, Hydralazine, and Tienilic Acid; Abbreviations; 4.1 Introduction; 4.2 Acetaminophen; 4.2.1 Metabolism of Acetaminophen; 4.2.2 Metabolic Activation of Acetaminophen 4.3 Halothane |
| Record Nr. | UNINA-9910141385203321 |
Kalgutkar Amit S. <1965->
|
||
| Weinheim, : Wiley-VCH, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Reactive drug metabolites [[electronic resource] /] / Amit S. Kalgutkar ...[et. al.]
| Reactive drug metabolites [[electronic resource] /] / Amit S. Kalgutkar ...[et. al.] |
| Autore | Kalgutkar Amit S. <1965-> |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2012 |
| Descrizione fisica | 1 online resource (403 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) | KalgutkarAmit S. <1965-> |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Free radicals (Chemistry) - Physiological effect
Drugs - Metabolism |
| ISBN |
3-527-65574-3
1-283-60402-7 9786613916471 3-527-65576-X 3-527-65577-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Reactive Drug Metabolites; Contents; Preface; A Personal Foreword; 1 Origin and Historical Perspective on Reactive Metabolites; Abbreviations; 1.1 Mutagenesis and Carcinogenesis; 1.2 Detection of Reactive Metabolites; 1.3 Induction and Inhibition: Early Probes for Reactive Metabolites and Hepatotoxicants; 1.4 Covalent Binding and Oxidative Stress: Possible Mechanisms of Reactive Metabolite Cytotoxicity; 1.5 Activation and Deactivation: Intoxication and Detoxification; 1.6 Genetic Influences on Reactive Metabolite Formation
1.7 Halothane: the Role of Reactive Metabolites in Immune-Mediated Toxicity1.8 Formation of Reactive Metabolites, Amount Formed, and Removal of Liability; 1.9 Antibodies: Possible Clues but Inconclusive; 1.10 Parent Drug and Not Reactive Metabolites, Complications in Immune-Mediated Toxicity; 1.11 Reversible Pharmacology Should not be Ignored as a Primary Cause of Side Effects; 1.12 Conclusions: Key Points in the Introduction; References; 2 Role of Reactive Metabolites in Genotoxicity; Abbreviations; 2.1 Introduction; 2.2 Carcinogenicity of Aromatic and Heteroaromatic Amines 2.3 Carcinogenicity of Nitrosamines2.4 Carcinogenicity of Quinones and Related Compounds; 2.5 Carcinogenicity of Furan; 2.6 Carcinogenicity of Vinyl Halides; 2.7 Carcinogenicity of Ethyl Carbamate; 2.8 Carcinogenicity of Dihaloalkanes; 2.9 Assays to Detect Metabolism-Dependent Genotoxicity in Drug Discovery; 2.10 Case Studies in Eliminating Metabolism-Based Mutagenicity in Drug Discovery Programs; References; 3 Bioactivation and Inactivation of Cytochrome P450 and Other Drug-Metabolizing Enzymes; Abbreviations; 3.1 Introduction 3.2 Pharmacokinetic and Enzyme Kinetic Principles Underlying Mechanism-Based Inactivation and Drug-Drug Interactions3.2.1 Enzyme Kinetic Principles of Mechanism-Based Inactivation; 3.2.2 Pharmacokinetic Principles Underlying DDIs Caused by Mechanism-Based Inactivation; 3.3 Mechanisms of Inactivation of Cytochrome P450 Enzymes; 3.3.1 Quasi-Irreversible Inactivation; 3.3.2 Heme Adducts; 3.3.3 Protein Adducts; 3.4 Examples of Drugs and Other Compounds that are Mechanism-Based Inactivators of Cytochrome P450 Enzymes; 3.4.1 Amines; 3.4.2 Methylenedioxyphenyl Compounds 3.4.3 Quinones, Quinone Imines, and Quinone Methides3.4.4 Thiophenes; 3.4.5 Furans; 3.4.6 Alkynes; 3.4.7 2-Alkylimidazoles; 3.4.8 Other Noteworthy Cytochrome P450 Inactivators; 3.5 Mechanism-Based Inactivation of Other Drug-Metabolizing Enzymes; 3.5.1 Aldehyde Oxidase; 3.5.2 Monoamine Oxidases; 3.6 Concluding Remarks; References; 4 Role of Reactive Metabolites in Drug-Induced Toxicity - The Tale of Acetaminophen, Halothane, Hydralazine, and Tienilic Acid; Abbreviations; 4.1 Introduction; 4.2 Acetaminophen; 4.2.1 Metabolism of Acetaminophen; 4.2.2 Metabolic Activation of Acetaminophen 4.3 Halothane |
| Record Nr. | UNINA-9910830512703321 |
|
Kalgutkar Amit S. <1965->
|
||
| Weinheim, : Wiley-VCH, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Reactive drug metabolites / / Amit S. Kalgutkar ...[et. al.]
| Reactive drug metabolites / / Amit S. Kalgutkar ...[et. al.] |
| Autore | Kalgutkar Amit S. <1965-> |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2012 |
| Descrizione fisica | 1 online resource (403 p.) |
| Disciplina | 615.19 |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Free radicals (Chemistry) - Physiological effect
Drugs - Metabolism |
| ISBN |
9786613916471
9783527655748 3527655743 9781283604024 1283604027 9783527655762 352765576X 9783527655779 3527655778 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Reactive Drug Metabolites; Contents; Preface; A Personal Foreword; 1 Origin and Historical Perspective on Reactive Metabolites; Abbreviations; 1.1 Mutagenesis and Carcinogenesis; 1.2 Detection of Reactive Metabolites; 1.3 Induction and Inhibition: Early Probes for Reactive Metabolites and Hepatotoxicants; 1.4 Covalent Binding and Oxidative Stress: Possible Mechanisms of Reactive Metabolite Cytotoxicity; 1.5 Activation and Deactivation: Intoxication and Detoxification; 1.6 Genetic Influences on Reactive Metabolite Formation
1.7 Halothane: the Role of Reactive Metabolites in Immune-Mediated Toxicity1.8 Formation of Reactive Metabolites, Amount Formed, and Removal of Liability; 1.9 Antibodies: Possible Clues but Inconclusive; 1.10 Parent Drug and Not Reactive Metabolites, Complications in Immune-Mediated Toxicity; 1.11 Reversible Pharmacology Should not be Ignored as a Primary Cause of Side Effects; 1.12 Conclusions: Key Points in the Introduction; References; 2 Role of Reactive Metabolites in Genotoxicity; Abbreviations; 2.1 Introduction; 2.2 Carcinogenicity of Aromatic and Heteroaromatic Amines 2.3 Carcinogenicity of Nitrosamines2.4 Carcinogenicity of Quinones and Related Compounds; 2.5 Carcinogenicity of Furan; 2.6 Carcinogenicity of Vinyl Halides; 2.7 Carcinogenicity of Ethyl Carbamate; 2.8 Carcinogenicity of Dihaloalkanes; 2.9 Assays to Detect Metabolism-Dependent Genotoxicity in Drug Discovery; 2.10 Case Studies in Eliminating Metabolism-Based Mutagenicity in Drug Discovery Programs; References; 3 Bioactivation and Inactivation of Cytochrome P450 and Other Drug-Metabolizing Enzymes; Abbreviations; 3.1 Introduction 3.2 Pharmacokinetic and Enzyme Kinetic Principles Underlying Mechanism-Based Inactivation and Drug-Drug Interactions3.2.1 Enzyme Kinetic Principles of Mechanism-Based Inactivation; 3.2.2 Pharmacokinetic Principles Underlying DDIs Caused by Mechanism-Based Inactivation; 3.3 Mechanisms of Inactivation of Cytochrome P450 Enzymes; 3.3.1 Quasi-Irreversible Inactivation; 3.3.2 Heme Adducts; 3.3.3 Protein Adducts; 3.4 Examples of Drugs and Other Compounds that are Mechanism-Based Inactivators of Cytochrome P450 Enzymes; 3.4.1 Amines; 3.4.2 Methylenedioxyphenyl Compounds 3.4.3 Quinones, Quinone Imines, and Quinone Methides3.4.4 Thiophenes; 3.4.5 Furans; 3.4.6 Alkynes; 3.4.7 2-Alkylimidazoles; 3.4.8 Other Noteworthy Cytochrome P450 Inactivators; 3.5 Mechanism-Based Inactivation of Other Drug-Metabolizing Enzymes; 3.5.1 Aldehyde Oxidase; 3.5.2 Monoamine Oxidases; 3.6 Concluding Remarks; References; 4 Role of Reactive Metabolites in Drug-Induced Toxicity - The Tale of Acetaminophen, Halothane, Hydralazine, and Tienilic Acid; Abbreviations; 4.1 Introduction; 4.2 Acetaminophen; 4.2.1 Metabolism of Acetaminophen; 4.2.2 Metabolic Activation of Acetaminophen 4.3 Halothane |
| Record Nr. | UNINA-9911019979103321 |
|
Kalgutkar Amit S. <1965->
|
||
| Weinheim, : Wiley-VCH, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||